Cardiovascular Event, Parkinson Disease
Conditions
Keywords
Parkinson's Disease, cardiovascular events, Levodopa
Brief summary
Cardiovascular (CV) disease is a common comorbidity of Parkinson's disease (PD). The background incidence rate of CV events in a levodopa-treated PD population was assessed to better understand these comorbidities in the PD population. One objective of the study is to identify a population of prevalent PD patients with incident levodopa use within the years 2004-2010 on the Integrated Health Care Information Services (IHCIS) database. The second objective is to report the incidence of CV events overall and during intervals 0-6, 6-12 and 12-18 months after first prescription of levodopa among all new levodopa users.
Interventions
DRUGlevodopa
levodopa use
Sponsors
GlaxoSmithKline
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Individuals with one or more prescriptions of levodopa between 1st July 2004 and 30th June 2010 * Individuals on the database with medical and pharmacy benefit for at least 6 months prior to date of first prescription of levodopa * Individuals with one or more diagnosis codes for Parkinson's disease within the 6 months prior or 6 months post first prescription of levodopa
Exclusion criteria
* Individuals less than 20 years of age on date of first prescription of levodopa * Individuals previously prescribed levodopa prior to study period
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall occurrence of CV events | 0-18 months overall after first prescription of levodopa |
| Occurrence of CV events during first 6 months | 0-6 months after first prescription of levodopa |
| Occurrence of CV events during second 6 months | 6-12 months after first prescription of levodopa |
| Occurrence of CV events during third 6 months | 12-18 months after first prescription of levodopa |
Outcome results
None listed